$14.06
0.36%
Nasdaq, Nov 19, 04:00 pm EST. Closed.
ISIN
US5502491062
Symbol
LMRI

Lumexa Imaging Stock price

$14.06
+3.34 31.16% 1M
+7.06 100.86% 6M
-4.44 24.00% YTD
-4.44 24.00% 1Y
-4.44 24.00% 3Y
-4.44 24.00% 5Y
-4.44 24.00% 10Y
-4.44 24.00% 20Y
Nasdaq, Closing price Thu, Nov 19 2026
+0.05 0.36%
ISIN
US5502491062
Symbol
LMRI

Is Lumexa Imaging a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,085 stocks worldwide.

Key metrics

Basic
Market capitalization
$1.4b
Enterprise Value
$2.2b
Net debt
$820.2m
Cash
$69.7m
Shares outstanding
96.1m
Valuation
P/E
negative
P/S | estimate
0.9 | 1.2
EV/Sales | estimate
1.4 | 2.0
EV/FCF | ex SBC
157.9 | negative
P/B
2.2
Financial Health
Equity Ratio
33.2%
Return on Equity
-8.0%
ROCE
2.2%
ROIC
3.9%
Debt/Equity
1.4
Share-Based Compensation & Dilution
SBC | % of Revenue
$66.6m | 4.3%
SBC as % of FCF
484.5%
SBC Growth 1Y
-
Share Count Growth 1Y
-
Shareholder Yield
-
Financials
Revenue | estimate
$1.5b | $1.1b
EBITDA
$96.0m
EBIT
$35.7m
Net Income
$-42.6m
Free Cash Flow | ex SBC
$13.8m | $-52.9m
Growth
Revenue | estimate
- | 6.7%
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Margin
Gross
15.0%
EBITDA
6.2%
EBIT
2.3%
Net
-2.8%
Free Cash Flow | ex SBC
0.9% | -3.4%
More
EPS
$-0.4
FCF per Share
$0.1
Short interest
7.0%
Employees
-
Rev per Employee
-

Lumexa Imaging Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Lumexa Imaging forecast:

15x Buy
94%
1x Hold
6%

Analyst Opinions

16 Analysts have issued a Lumexa Imaging forecast:

Buy
94%
Hold
6%

Lumexa Imaging Events

Past Events
NOV
10
Q3 2026 Earnings Call
9 days ago
AUG
12
Q2 2026 Earnings Call
3 months ago
MAY
12
Q1 2026 Earnings Call
6 months ago
MAR
26
Q4 2025 Earnings Call
8 months ago
MAR
10
Barclays 28th Annual Global Healthcare Conference
8 months ago

Financial data from Lumexa Imaging

Jun '26
+/-
%
1,540 1,540
-
100%
- Direct Costs 1,309 1,309
-
85%
231 231
-
15%
- Selling and Administrative Expenses 135 135
-
9%
- Research and Development Expense - -
-
-
96 96
-
6%
- Depreciation and Amortization 60 60
-
4%
EBIT (Operating Income) EBIT 36 36
-
2%
Net Profit -43 -43
-
-3%

In millions USD.

Don't miss a Thing! We will send you all news about Lumexa Imaging directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lumexa Imaging Stock News

Neutral
GlobeNewsWire
●
4 days ago
New de novo center openings build presence in attractive markets and support long-term growth plans New de novo center openings build presence in attractive markets and support long-term growth plans
Neutral
GlobeNewsWire
●
8 days ago
10th Health System joint venture expands Lumexa Imaging's geographic footprint and advances its disciplined growth strategy 10th Health System joint venture expands Lumexa Imaging's geographic footprint and advances its disciplined growth strategy
More Lumexa Imaging News

Company Profile

Lumexa Imaging Holdings, Inc. engages in providing diagnostic imaging services. The company is headquartered in Raleigh, North Carolina and currently employs 4,064 full-time employees. The company went IPO on 2025-12-11. The firm offers a range of advanced imaging services (MRI, CT and PET scans) and routine diagnostic and screening imaging services (X-ray, ultrasound and mammography). The Company’s segments include Outpatient Imaging Centers (Outpatient) and Professional Services (Professional). The Outpatient segment consists of imaging centers that are owned or operated by it (either wholly owned or via unconsolidated affiliate), where it performs the imaging scan and provides the radiologist’s interpretation service. The Professional segment consists of professional interpretation services, where the imaging scan itself is performed at the hospital or point of care and not by it or its unconsolidated affiliates. The firm and its affiliates operate outpatient imaging center footprint in the United States, spanning 184 centers across 13 states and includes eight joint venture partnerships with health systems.

Head office United States
CEO Ms. Zulla
Website www.lumexaimaging.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today